Amgen, Swedish Orphan Biovitrum sales and marketing update

Swedish Orphan will return co-promotion rights in Nordic countries to Amgen for Mimpara cinacalcet. Swedish Orphan will receive an undisclosed payment for the return of rights under the 2003 deal. The second-generation calcimimetic is marketed to treat secondary hyperparathyroidism during maintenance dialysis and hypercalcemia in parathyroid carcinoma patients and to manage hypercalcemia in patients with primary hyperparathyroidism when surgery is not an option. The company reported SEK26.2 million ($3.9 million) in 2009 co-promotion revenue for Mimpara. Amgen, which has rights to cinacalcet from NPS Pharmaceuticals Inc. (NASDAQ:NPSP, Bedminster, N.J.), markets it in the U.S. as Sensipar. ...